Skip to main content

Leading the transformation of care

AbbVie is translating its expertise in hematologic malignancies to advance cancer care for people diagnosed with solid tumors.

With the incidence of cancer set to continuously rise over the coming years, cancer represents a complex and unrelenting healthcare challenge.1,2  The UK still lags behind Europe when it comes to cancer patient outcomes and access to innovative treatments.2  By working collaboratively with the NHS and cancer community, we want UK cancer patients to receive the highest quality care in Europe.

AbbVie is committed to transforming standards of care in the treatment and management of blood cancers such as, Chronic Lymphocitic Leukaemia (CLL) and Acute Myeloid Leukaemia (AML) where there is significant unmet need.

We are translating this expertise in hematologic malignancies to advance cancer care for people diagnosed with solid tumors.


  1. Cancer Research UK. What is Cancer? Available at:
  2. IHE. Comparator Report on Patient Access To Cancer Medicines In Europe Revisited-A UK Perspective. Available at:

February 2023